UY28539A1 - Derivados de iminoácidos bicíclicos como inhibidores de metaloproteinasas de matriz - Google Patents

Derivados de iminoácidos bicíclicos como inhibidores de metaloproteinasas de matriz

Info

Publication number
UY28539A1
UY28539A1 UY28539A UY28539A UY28539A1 UY 28539 A1 UY28539 A1 UY 28539A1 UY 28539 A UY28539 A UY 28539A UY 28539 A UY28539 A UY 28539A UY 28539 A1 UY28539 A1 UY 28539A1
Authority
UY
Uruguay
Prior art keywords
matrix
metaloprotein
inhibitors
derivatives
imino acids
Prior art date
Application number
UY28539A
Other languages
English (en)
Inventor
Dr Hans Matter
Dr Manfred Schudok
Dr Armin Hofmeister
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of UY28539A1 publication Critical patent/UY28539A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula I, contenidos en productos farmacéuticos par la profilaxis y terapia de enfermedades cuya evolución incluye un aumento de la actividad de metaloproteinasas de matriz, del tipo degenerativa de las articulaciones, o enfermedades periodontales, o enfermedad crónica del aparato locomotor o pertubaciones del metabolismo óseo o una enfermedad inflamatoria o enfermedad cancerígena, caquexia, anorexia o choque séptico.
UY28539A 2003-09-27 2004-09-27 Derivados de iminoácidos bicíclicos como inhibidores de metaloproteinasas de matriz UY28539A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10344936A DE10344936A1 (de) 2003-09-27 2003-09-27 Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen

Publications (1)

Publication Number Publication Date
UY28539A1 true UY28539A1 (es) 2005-04-29

Family

ID=34353126

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28539A UY28539A1 (es) 2003-09-27 2004-09-27 Derivados de iminoácidos bicíclicos como inhibidores de metaloproteinasas de matriz

Country Status (24)

Country Link
EP (1) EP1670766B1 (es)
JP (1) JP4861179B2 (es)
KR (1) KR20060086367A (es)
CN (1) CN1856478B (es)
AR (1) AR046165A1 (es)
AT (1) ATE550327T1 (es)
AU (1) AU2004275937A1 (es)
BR (1) BRPI0414594A (es)
CA (1) CA2539731A1 (es)
DE (1) DE10344936A1 (es)
IL (1) IL174040A0 (es)
MA (1) MA28075A1 (es)
ME (1) MEP33008A (es)
MX (1) MXPA06002927A (es)
MY (1) MY139830A (es)
NO (1) NO20061837L (es)
NZ (1) NZ546158A (es)
PE (1) PE20050432A1 (es)
RS (1) RS20060194A (es)
RU (1) RU2335494C2 (es)
TW (1) TW200520755A (es)
UY (1) UY28539A1 (es)
WO (1) WO2005030728A1 (es)
ZA (1) ZA200601501B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102005002500A1 (de) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
ES2658964T3 (es) 2007-08-03 2018-03-13 Nucitec S.A. De C.V. Composiciones y métodos para el tratamiento y la prevención de la osteoartritis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (es) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
CN1131215C (zh) * 1995-11-13 2003-12-17 赫彻斯特股份公司 环和杂环N－取代的α－亚氨基异羟肟酸和羧酸
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
DE69807845T2 (de) * 1997-01-23 2003-06-05 Hoffmann La Roche Sulfamide-metalloprotease inhibitoren
DE10300015A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln

Also Published As

Publication number Publication date
MXPA06002927A (es) 2006-06-14
CN1856478A (zh) 2006-11-01
NO20061837L (no) 2006-06-01
BRPI0414594A (pt) 2006-11-07
PE20050432A1 (es) 2005-07-21
CA2539731A1 (en) 2005-04-07
AU2004275937A1 (en) 2005-04-07
KR20060086367A (ko) 2006-07-31
JP4861179B2 (ja) 2012-01-25
IL174040A0 (en) 2006-08-01
RS20060194A (en) 2008-08-07
NZ546158A (en) 2008-11-28
JP2007506690A (ja) 2007-03-22
AR046165A1 (es) 2005-11-30
WO2005030728A1 (de) 2005-04-07
MA28075A1 (fr) 2006-08-01
CN1856478B (zh) 2010-05-26
TW200520755A (en) 2005-07-01
ATE550327T1 (de) 2012-04-15
RU2006114352A (ru) 2006-08-27
EP1670766B1 (de) 2012-03-21
MY139830A (en) 2009-10-30
RU2335494C2 (ru) 2008-10-10
DE10344936A1 (de) 2005-04-21
MEP33008A (en) 2010-10-10
EP1670766A1 (de) 2006-06-21
ZA200601501B (en) 2007-04-25

Similar Documents

Publication Publication Date Title
EA201790122A1 (ru) Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение
PA8580501A1 (es) Derivados de indol o derivados de bencimidazol para modular ikb quinasa
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
BR0318383A (pt) derivados de pirazoloisoquinolina como inibidores de cinase
DK1611088T3 (da) Hydroxymater som terapeutiske midler
IS8175A (is) Píperasín afleiður og aðferðir við notkun þeirra
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
UY27626A1 (es) Nuevos compuestos heterocíclos, activos como inhibidores de beta-lactamasas
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
UY27939A1 (es) Compuestos
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
UY30500A1 (es) Compuestos de azabencimidazolilo
UY28483A1 (es) Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migración de macrófagos y su uso en el tratamiento de enfermedades en el hombre
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY30835A1 (es) 8-alquinilxantinas y derivados
EA200700909A1 (ru) Азаиндолкарбоксамиды
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
EA201492127A1 (ru) Пролекарственные производные (е)-n-метил-n-((3-метилбензофуран-2-ил)метил)-3-(7-оксо-5,6,7,8-тетрагидро-1,8-нафтиридин-3-ил)акриламида
PA8622801A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
ECSP088963A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden
BRPI0509468A (pt) 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120322